Exome Asset Management’s Tarsus Pharmaceuticals TARS Stock Holding History

Exome Asset Management’s Portfolio TARS Stock Details TARS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-28,178	Closed	-$1.56M	–	82
2024 Q4	$1.56M	Sell	28,178 -17,422	-38%	-$791K	1.17%	34
2024 Q3	$1.5M	Buy	+45,600	New	+$1.28M	1.01%	43
2024 Q2	–	Sell	-66,300	Closed	-$2.41M	–	72
2024 Q1	$2.41M	Sell	66,300 -18,100	-21%	-$532K	2.06%	18
2023 Q4	$1.71M	Buy	+84,400	New	+$1.41M	1.69%	26

Other funds holding TARS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Exome Asset Management's TARS Position: Q1 2025 in Review

Exome Asset Management sold out of Tarsus Pharmaceuticals (TARS) in Q1 2025, closing a stake of 28,178 shares — an estimated $1.56M sold.

Exome Asset Management first reported a position in TARS in Q4 2023 and held it in 4 quarters. The position peaked at $2.41M in Q1 2024. 194 funds tracked by Wall St. Rank hold TARS as of Q1 2025.

Exome Asset Management reported no remaining Tarsus Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Exome Asset Management sold 28,178 Tarsus Pharmaceuticals shares in Q1 2025, an estimated $1.56M.
Exome Asset Management first reported a position in Tarsus Pharmaceuticals in Q4 2023 and held it in 4 quarters.
Exome Asset Management's Tarsus Pharmaceuticals position peaked at $2.41M in Q1 2024.
194 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q1 2025.

Based on Exome Asset Management's 13F filing for Q1 2025, filed 15 May 2025.